NCT00982189

Cardiovascular Prevention for Persons With HIV

Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Hennepin Healthcare Research Institute · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This study is funded by the American Heart Association. The goal of this research is to prevent early cardiovascular damage before symptoms develop for persons with HIV infection. Evidence suggests that taking low doses of blood pressure and cholesterol medication reduces risk for heart disease in persons who are at increased risk (such as the case with HIV infection). Participants who are taking HIV treatment with an 'undetectable' viral load, and who do NOT need treatment for high blood pressure or cholesterol may be eligible to enroll. Participants will take a low dose cholesterol medication (or placebo) and a low dose of a blood pressure medication (or a placebo), and will be seen at 3 study visits over 4 months.

Conditions

• HIV Infection
• Cardiovascular Disease Risk

Interventions

Type	Name	Description
DRUG	Pravastatin	Participants randomized to take pravastatin (active) or matching placebo pill once daily
DRUG	Lisinopril	Participants randomized to take lisinopril (active) or matching placebo pill once daily

Timeline

• Start date: 2009-09-01
• Primary completion: 2010-12-01
• Completion: 2011-05-01
• First posted: 2009-09-23
• Last updated: 2017-11-22
• Results posted: 2012-04-18

Locations

1 site across 1 country: United States